This pilot study will aim to understand the potential benefit of the assessment of walking
using video slow motion for muscle selection and the development of an image catalogue guide
of the potential results of injection of abobotulinumtoxinA by comparing foot postures before
and after injection. The objective is to evaluate the use of video assessment to improve
muscle selection for the injection of botulinum toxin A to improve walking outcomes. Primary
outcomes include: self-selected velocity (SSV), maximal velocity (MV) and symmetry of
walking. Secondary outcomes include: passive range of motion (PROM), Modified Ashworth Scale
(MAS) and the Tardieu Scale (TS). Fifteen persons post stroke or TBI over age 18 with
equinovarus foot deformity who are able to ambulate will be included in the study. Dysport
1000 to 1500 units will be used to be distributed on the basis of clinical indication to
ankle plantar flexors (gastrocnemius and soleus), tibialis posterior and long toe flexors.
The duration of subjects' participation is 4-6 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Albert Einstein Healthcare Network
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A onabotulinumtoxinA